Acrivon Therapeutics, Inc. Operating Cash Flow
Acrivon Therapeutics, Inc. (ACRV) reported Operating Cash Flow of -$35.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$14.86M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$20.54M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.24M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.28M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$63.66M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$65.67M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$42.64M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$30.12M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$35.40M 10-Q · filed 2026-08-12 | -$50.64M derived: sum of 3 quarters · filed 2026-08-12 | -$62.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$20.54M 10-Q · filed 2026-05-13 | -$35.77M derived: sum of 2 quarters · filed 2026-05-13 | -$48.06M derived: sum of 3 quarters · filed 2026-05-13 | -$64.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$15.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$27.52M derived: sum of 2 quarters · filed 2026-03-19 | -$44.13M derived: sum of 3 quarters · filed 2026-08-12 | -$63.66M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$12.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$28.89M derived: sum of 2 quarters · filed 2026-08-12 | -$48.43M 10-Q · filed 2025-11-13 | -$65.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$16.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$36.15M 10-Q · filed 2026-08-12 | -$53.51M derived: sum of 3 quarters · filed 2026-08-12 | -$70.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$19.54M 10-Q · filed 2026-05-13 | -$36.90M derived: sum of 2 quarters · filed 2026-05-13 | -$54.22M derived: sum of 3 quarters · filed 2026-05-13 | -$68.12M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$17.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$34.68M derived: sum of 2 quarters · filed 2026-03-19 | -$48.59M derived: sum of 3 quarters · filed 2026-03-19 | -$65.67M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$17.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$31.23M derived: sum of 2 quarters · filed 2025-11-13 | -$48.31M 10-Q · filed 2025-11-13 | -$60.67M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$13.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$30.99M 10-Q · filed 2025-08-13 | -$43.35M derived: sum of 3 quarters · filed 2025-08-13 | -$53.16M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$17.08M 10-Q · filed 2025-05-14 | -$29.45M derived: sum of 2 quarters · filed 2025-05-14 | -$39.26M derived: sum of 3 quarters · filed 2025-05-14 | -$48.37M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$22.17M derived: sum of 2 quarters · filed 2025-03-27 | -$31.28M derived: sum of 3 quarters · filed 2025-03-27 | -$42.64M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$9.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$18.92M derived: sum of 2 quarters · filed 2024-11-13 | -$30.27M 10-Q · filed 2024-11-13 | -$39.63M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$9.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$20.47M 10-Q · filed 2024-08-13 | -$29.82M derived: sum of 3 quarters · filed 2024-08-13 | -$36.34M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$11.36M 10-Q · filed 2024-05-14 | -$20.71M derived: sum of 2 quarters · filed 2024-05-14 | -$27.23M derived: sum of 3 quarters · filed 2024-05-14 | -$33.06M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$9.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$15.88M derived: sum of 2 quarters · filed 2024-03-28 | -$21.70M derived: sum of 3 quarters · filed 2024-03-28 | -$30.12M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$6.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$12.35M derived: sum of 2 quarters · filed 2023-11-09 | -$20.76M 10-Q · filed 2023-11-09 | -$24.39M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$5.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$14.24M 10-Q · filed 2023-08-11 | -$17.87M derived: sum of 3 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$8.42M 10-Q · filed 2023-05-09 | -$12.04M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$13.98M 10-K · filed 2023-03-28 | ||
| 2021-09-30 | -$10.36M 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |